Company

SDK Therapeutics

Biotechnology Research The Significant Treatment Burden Associated with the Current Intravenous Formulation. the Sdk Team Is on Track to File an Ind in 2024 and Initiate Sdk001 Clinical Program in Q1 2025. More Exciting News to Be Shared Shortly. 3 employees

Employees: 3
Contacts: 2
Emails: 2
Phones: 2

sdktx.com LinkedIn

SDK Therapeutics Overview

Headquarters: The Significant Treatment Burden Associated with the Current Intravenous Formulation. the Sdk Team Is on Track to File an Ind in 2024 and Initiate Sdk001 Clinical Program in Q1 2025. More Exciting News to Be Shared Shortly.
Website: sdktx.com
Industry: Biotechnology Research
Employees: 3
Founded: 2024
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Hematology Oncology Rase Diseases

About SDK Therapeutics

The mission of SDK Therapeutics is to develop and commercialize medicines in hematology, oncology, and rare disease to improve the life of patients.

SDK Therapeutics Contact Details

People in AeroLeads: 2
With contact data: 2
Email contacts: 2; 100.0% coverage
Phone contacts: 2; 100.0% coverage

SDK Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Stephane Berthier	Founder & CEO at Sdk Therapeutics	United States	Email Phone
Benjamin Looker	General Counsel and Board Member	Boston, Massachusetts, United States	Email Phone